August 2024 – Page 18

Lilly’s Blockbuster GLP-1 Drugs Removed from FDA Shortage List

9 months ago talkbio0Tagged Drug Shortage, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, United States Food and Drug Administration, Zepbound

Lilly, GLP-1, FDA, drug shortage, Mounjaro, Zepbound, tirzepatide

Novo Nordisk Expands Legal Campaign Against Compounders of GLP-1 Drugs

9 months ago talkbio0Tagged Compound, Glucagon-Like Peptide 1, legal campaign, Nordisk, patient safety, semaglutide

Novo Nordisk, GLP-1 drugs, compounded drugs, legal campaign, patient safety, semaglutide

FDA Approves Servier’s Brain Cancer Drug, Triggering $1 Billion Payout for Agios

9 months ago talkbio0Tagged Agios, Approved, Blood - brain barrier anatomy, Brain Neoplasms, cancer metabolism, IDH1 gene, IDH2 gene, Mutation, payment, Royalty, Servier, United States Food and Drug Administration, Voranigo

FDA approval, Servier, brain cancer drug, Voranigo, Agios Pharmaceuticals, IDH1 and IDH2 mutations, blood-brain barrier, cancer metabolism, royalty payments

Stoke Therapeutics Advances Dravet Syndrome Drug to Phase III Trials After FDA Lifts Partial Clinical Hold

9 months ago talkbio0Tagged Activator, Infantile Severe Myoclonic Epilepsy, orphan drug designation, pediatric disease designation, Phase 3 Clinical Trials, SCN1A gene, Stoke, United States Food and Drug Administration, Zorevunersen

Stoke Therapeutics, Dravet syndrome, Phase III trials, FDA, zorevunersen, SCN1A activator, orphan drug designation, rare pediatric disease designation

Aeterna Zentaris Rebrands as COSCIENS Biopharma: A New Era in Biopharmaceuticals

9 months ago talkbio0Tagged Adult, Aeterna Zentaris, Biological Factors, Biopharma, Changing, COSCIENS, development aspects, Diagnostic tests, Macrilen, rebranding, Somatotropin deficiency

Aeterna Zentaris, COSCIENS Biopharma, biopharmaceuticals, rebranding, name change, therapeutic development, diagnostic tests, Macrilen, adult growth hormone deficiency